Kevin Tang bought $277K of Boundless Bio (BOLD)

Executed Oct 16, disclosed Oct 20, 4 days later.

Value, as filed

$277K

118,185 sh × $2.34

Executed

Oct 16

the trade date, as filed

Disclosed

Oct 20

4 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

not yet measured

Not yet measured: the 21-session window has not closed, or the prices around it are not on record.

The filer

Kevin Tang Director profile →

Kevin Tang (Director) filed 9 Form 4 reports in the trailing twelve months (9 purchases, 0 sales), most often in Aurinia Pharmaceuticals Inc. (AUPH). Across 8 priced purchase filings, the average 21-session return was +4.8% from execution and +6.8% from disclosure (delay-adjusted; derived). The largest single filing was $12.7M of AUPH (898,400 sh across 5 lots, as filed), executed Feb 27.

The name

BOLD

Boundless Bio, Inc. BOLD · Healthcare · 5 filings in 24 months ticker →

Healthcare · Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Kevin Tang in BOLD

BOLDPURCHASE Boundless Bio, Inc. $107K
43,878 sh × $2.43
Exec Jul 14
Filed Jul 16 · 8:10 PM ET BOLDPURCHASE Boundless Bio, Inc. $222K
91,578 sh across 2 lots
Exec Jul 10
Filed Jul 13 · 7:06 PM ET BOLDPURCHASE Boundless Bio, Inc. $178K
71,612 sh × $2.49
Exec Jul 1
Filed Jul 2 · 7:45 PM ET BOLDPURCHASE Boundless Bio, Inc. $711K
284,912 sh across 3 lots
Exec Jun 25
Filed Jun 29 · 7:56 PM ET